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Background. The risk-benefit ratio of cyclosporine A (CsA) is
much more critical in some auto-immune diseases in comparison
to transplantation medicine, due to its renal toxic potential. The
present meta-analysis is based on an a priori defined methodology,
and is linked with a review of CsA-induced morphological lesions,
in order to draw relevant conclusions with regard to CsA-induced
nephrotoxicity in auto-immune diseases.
Methods. Only controlled, randomized trials with a treatment
period of two months or more, published from January 1979 to
August 1996, were selected for the evaluation of functional renal
impairment due to CsA treatment. To assess the risk of develop-
ing nephrotoxicity during CsA therapy, individual peak rises in
serum creatinine level were compared between the CsA-treated
group and the control group. Nephrotoxicity was defined as an
increase in serum creatinine level of 50% or more above baseline
at least once during the study period. Papers reporting CsA-
induced renal morphological lesions were reviewed.
Results. A risk difference of 20.9% for developing nephrotox-
icity, between a therapy with CsA and an alternative therapy, was
found. Already after a treatment period of 12 months with low
dose CsA (#5 mg/kg/day), de novo nonspecific morphological
damage could be induced in patients with auto-immune diseases.
Conclusions. From this analysis of the literature, it is obvious
that a therapy with CsA in patients affected by auto-immune
diseases is not without risk. A rigorous evaluation of the risk-
benefit ratio is strongly recommended for each patient, with strict
monitoring of serum creatinine and CsA trough levels during
treatment. Renal biopsies during treatment must be seriously
taken into consideration in patients who develop even a slight
renal functional impairment, particularly when prolonged therapy
of longer than one year, even with low dose CsA (#5 mg/kg/day),
is given.
The introduction of CsA in clinical practice [1] has meant
a substantial progression in transplantation medicine [2, 3].
This has resulted in a successful broadening of the indica-
tions for cyclosporine to the treatment of auto-immune
diseases (Table 1) [4–17].
However, a major disadvantage of CsA is its renal
toxicity. Three different forms of cyclosporine nephrotox-
icity can be distinguished: reversible acute renal dysfunc-
tion, hemolytic-uremic like syndrome and irreversible
chronic nephrotoxicity. This latter, causing irreversible
morphological alterations in the kidney, is the main draw-
back for the more widespread use of CsA. Although the
risk-benefit ratio of CsA therapy in transplantation medi-
cine is clearly in favor of its use, it is questionable whether
this is also the case for all forms of auto-immune diseases.
It has been documented in transplant patients that
irreversible renal histological lesions can already appear
after six months of high dose CsA therapy [18] with
progression over time even after CsA dose reduction [19].
There is less unanimity with regard to the long-term
nephrotoxic effect of low-dose regimens used in auto-
immune diseases. In these auto-immune diseases, a main-
tenance therapy with low dose CsA (#5 mg/kg/day) is often
required to maintain remission [20, 21]. The risk of neph-
rotoxicity has led to dosage guidelines, including an upper
dose limit of 5 mg/kg/day, as well as dose reduction if serum
creatinine is raised by more than 30% of pre-treatment
values [22, 23].
A meta-analysis of the literature concerning CsA-in-
duced nephrotoxicity limited to the domain of auto-im-
mune diseases is not available. The present meta-analysis is
based on an a priori defined methodology, and is linked
with a review of CsA-induced morphological lesions in
order to draw relevant conclusions with regard to CsA-
induced nephrotoxicity.
METHODS
Identification of relevant clinical studies evaluating renal
function
Data sources. To retrieve a maximum of relevant studies,
searches were done by two independent reviewers in two
different medical literature systems (January 1979 - August
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1996): Medline (National Library of Medicine®) and Tox-
line (National Library of Medicine®), using the following
key words in different combinations: cyclosporine, adverse
effects, nephrotoxicity, auto-immune diseases, uveitis, pso-
riasis, rheumatoid arthritis, inflammatory bowel disease.
Additional publications were identified from review pa-
pers and references of the selected papers. Any publication
identified as relevant was retrieved. Papers concerning
transplantation or renal diseases (idiopathic nephrotic syn-
drome, lupus, etc.) were excluded.
Study selection. Selection of the papers was done accord-
ing to pre-specified inclusion and exclusion criteria. The
two reviewers were blinded to the results of the studies and
disagreement was resolved by consensus. Open trials, re-
view papers, letters and case reports were excluded. Only
controlled, randomized trials with a treatment period of
two months or more were retained. Studies using a dose of
CsA of 10 mg/kg/day or more were excluded. Articles
containing the same data of the same research group,
previously published, were also excluded.
Authors of the selected papers wherein no individualized
data of each CsA-treated and each control patient was
reported, were contacted by mail to obtain the missing
information.
Data extraction. The following information was obtained
from each paper: study design, type of disease, outcome
measurements, number and age of study population and
control group, CsA dose, duration of treatment, renal
functional evaluation, reversibility of renal dysfunction
after CsA withdrawal, and concomitant medication.
Meta-analysis. Serum creatinine levels at the start (base-
line level) and end of the treatment period were compared
between the CsA-treated group and the control group. The
percentage increase in serum creatinine level in patient and
control group in each study was used to determine the
overall weighted percentage increase in serum creatinine
level of all studies (statistical software: BMDP®).
To assess the risk of developing nephrotoxicity during
CsA therapy, individual peak rises in the serum creatinine
level were compared between both groups. Nephrotoxicity
was defined as an increase in serum creatinine level of 50%
or more above baseline at least once during the study
period. A risk difference between the patient group and
control group to develop nephrotoxicity was calculated
using the methods described by Cochran [24] and DerSi-
monian and Laird [25]. The risk difference and correspond-
ing variance was calculated for each study, in order to
obtain a weighted average risk difference. The x2 analysis
was used to test for homogeneity between the results of the
different studies. In case of heterogeneity, an estimate of
the degree of variability (t factor) was determined, and the
weighted average risk difference was recalculated accord-
ingly [25]. This method is described fully in the Appendix
[26].
Identification of relevant clinical studies evaluating
morphological alterations
Studies evaluating morphological alterations cannot
meet the same requirements as studies evaluating renal
function, where determination of a single functional pa-
rameter can be performed. Randomized, controlled studies
with biopsies before and after treatment in both the
cyclosporine-treated group and the control group would be
most instructive, but are unethical. Therefore, we were
unable to perform a meta-analysis, and decided to give a
general review of CsA-induced morphological alterations.
The following studies were selected for the analysis of
cyclosporine-induced morphological lesions: studies com-
paring renal histology before and after CsA-therapy of each
CsA-treated patient, or studies comparing post-treatment
kidney biopsies of the CsA-treated group with biopsies of a
non-treated control group.
RESULTS
Functional evaluation of cyclosporine A-induced
nephrotoxicity
Systematic overview. Of the 423 papers found, a large
series of open trials, case reports and review papers were
eliminated (380 papers). The number of controlled studies
was 43, of which twenty-five papers were excluded for
different reasons (Table 2) [4, 9, 11, 12, 14, 27–46]. There
was no disagreement between the two reviewers in the
selection procedure, except for seven studies that were
rejected on the basis of consensus [35–41]. The latter
studies had a divergent study design in comparison to the
other studies: either there was a product besides CsA
included in the study protocol, or CsA was admitted
intravenously, or the study had no clear controlled design
during the entire period.
Table 1. Cyclosporine A-treated clinical conditions
-Psoriasis -Multiple sclerosis
-Atopic dermatitis -Myasthenia gravis
-Other dermatological diseases -Sclerodermia
-Auto-immune uveitis -Idiopathic nephrotic syndrome
-Rheumatoid arthritis -Recent-onset diabetes mellitus
-Crohn’s disease -Systemic lupus erythematosus
-Primary biliary cirrhosis
Table 2. Excluded papers
Number References
Non-randomized design 1 [27]
Treatment period ,2 months 4 [4, 28–30]
Cyclosporine A dose $ 10 mg/kg/day 4 [31–34]
Divergent study design 7 [35–41]
Duplicate information 3 [9, 42–43]
No exact renal data 4 [11, 12, 14, 44]
No measurement of renal function in
control group
2 [45, 46]
Total 25
Vercauteren et al: CsA nephrotoxicity in auto-immune diseases 537
Table 3 gives a description of the 18 selected papers [10,
47–63]. These studies had comparable inclusion and exclu-
sion criteria. Dose reductions of CsA were performed
whenever serum creatinine increased more than 30 to 50%
above baseline level. Trough levels of cyclosporine were
assessed in 15 of the 18 selected papers, values were
mentioned in 10 studies. As stated in the methods sections
of the articles, dose adjustments would be made whenever
the trough levels were too high. It is not clear from the
papers in how many cases a dose adjustment was per-
formed for this reason. In a few papers it was even
mentioned that the mean target CsA level was not achieved
because dose reductions were required to minimize neph-
rotoxicity. Different assays (RIA, monoclonal, polyclonal;
HPLC; serum, whole blood) were used, so it is difficult to
compare values of the trough levels.
The concomitant medication included steroids, antihy-
pertensive medication and topical therapies. Concomitant
medication with nephrotoxic potential or with interference
of CsA metabolism was used as exclusion criteria in the
selected papers. However, in 10 articles, NSAIDs were
given to some Csa treated and control patients with RA.
This was also the case with 5-ASA, which was used in two
studies (Crohn’s disease).
The mean CsA dose of all studies was 4.8 mg/kg/day (3 to
7.8 mg/kg/day) with a mean duration of treatment of 6.4
months (2 to 18 months).
Not all articles described the renal functional parameters
in detail, because the goal of their study was mainly the
evaluation of the efficacy of CsA. Also, not all authors
replied to the questionaire for extra information, as can be
seen in Table 3. The number of patients withdrawn from
the different studies was high (Table 3): 14 patients because
of renal dysfunction, the others for various reasons (ineffi-
cacy of the drug, gastro-intestinal symptoms, hirsutism,
depression, paraesthesia, tremor, complications of the dis-
ease, fever, convulsions, cancer, death, etc.). Only seven
studies clearly used the intention-to-treat principle.
The development of new onset hypertension was difficult
to evaluate, because of differences in definitions. In five
selected papers, it is even not clear whether or not hyperten-
sion was considered as adverse drug effect. In the remaining
13 papers, 83 out of 741 CsA treated patients (11.2%)
developed de novo hypertension, which was treated with salt
reduction, antihypertensive medication or CsA withdrawal.
With these measures, blood pressure was under control.
All the selected papers [10, 47–63] reported a statistically
significant rise in serum creatinine level for CsA-treated
patients, when compared with their baseline level. The
increase in serum creatinine level in the cyclosporine group
was significantly higher compared with the control group
(Table 4). However, in the study of Landewe´ et al [61],
serum creatinine increase was higher in the control group,
in which chloroquine was administered, than in the CsA-
treated group. The weighted percentage increase in serum
creatinine level of all studies was 17% in the CsA-treated
group (N 5 852) and 1.7% in the control group (N 5 763).
In several reports, this impairment of renal function
proved to be reversible after withdrawal of CsA (Table 4),
partially in seven studies [47–49, 52, 57, 58, 63], and
complete in six studies [10, 50, 54, 56, 60, 62]. However, the
Leiden group reported, in the follow-up [64] of their
placebo-controlled study [52], that the serum creatinine
Table 3. Description of selected studies
Study (et al) Date Ref. Study design Disease
Number
Mean age CsA dose
(mean)
mg/kg/day
Duration of
treatment
months
Extra information
received/ITT
CsA Control
(N withdrawals) CsA Control
Ahern MJ 1991 [47] DB, R, azathioprine-contr. RA 25 (7) 27 (12) 61 60 3.4 6 no/?
Berg KJ 1986 [48] DB, R, azathioprine-contr. RA 12 (2) 12 (5) 51 58 7.8 6 yes/no
Berg KJ 1989 [49] DB, R, placebo-contr. RA 26 (6) 19 (9) 50 50 4.4 12 yes/no
Boers M 1990 [50] DB, R, D-penic-contr. RA 46 (11) 46 (8) 58 56 5.0 6 no/yes
Brynskov J 1989 [10] DB, R, placebo-contr. Crohn 37 (10) 28 (12) 33 28 7.5 3 yes/?
de Vries J 1990 [51] DB, R, placebo-contr. Uveitis 14 (3) 13 (3) 45 46 NA (,10) 12 no/?
Dijkmans BAC 1987 [52] DB, R, placebo-contr. RA 17 (8) 19 (6) 54 55 7.5 6 no/?
Dougados M 1988 [53] DB, R, placebo-contr. RA 26 (4) 26 (2) 57 57 4.6 4 no/?
Feagan BG 1994 [54] DB, R, placebo-contr. Crohn 151 (58) 154 (41) 33 33 4.8 18 no/yes
Ferraccioli G 1995 [55] R, chloroquine-contr. CRD 12 (0) 12 (0) 56 55 5.0 2 yes/yes
Finzi A 1993 [56] R, etritinate-contr. Psoriasis 50 (2) 40 (7) 51 51 4.5 3 yes/?
Førre Ø 1994 [57] DB, R, placebo-contr. RA 61 (25) 61 (35) 52 50 3.9 11.5 no/yes
Heule F 1988 [58] DB, R, placebo-contr. Psoriasis 10 (?) 10 (?) 55 46 3.7 3 yes/?
Jewell DP 1994 [59] DB, R, placebo-contr. Crohn 72 (18) 74 (12) 36 33 5.0 3 no/yes
Kru¨ger K 1994 [60] DB, R, azathioprine-contr. RA 59 (12) 58 (12) 56 56 4.2 6 no/?
Landewe´ RBM 1994 [61] DB, R, chloroquine-contr. RA 22 (2) 22 (3) 48 50 3.6 6 no/?
Mahrle G 1995 [62] R, azathioprine-contr. Psoriasis 140 (2) 70 (2) 43 43 3.0 2.5 yes/yes
Tugwell P 1990 [63] DB, R, placebo-contr. RA 72 (10) 72 (22) 54 55 3.8 6 no/yes
Abbreviations are: DB, double-blind; R, randomized; RA, rheumatoid arthritis; CRD, chronic rheumatoid disease; NA, not available; ITT,
intention-to-treat analysis.
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level at two years after CsA withdrawal was still signifi-
cantly elevated above baseline (10%). Førre et al men-
tioned that in 6 patients out of 61, the mean serum
creatinine level was still 33% above baseline level, 20
months after CsA withdrawal [57]. In the ‘high-dose’ study
of Berg et al, one patient, with pre-treatment reduced renal
function, progressed to renal failure during and after CsA
treatment [48]. In their ‘low dose’ study, Berg et al reported
that the serum creatinine level was still 11.6% above
baseline three months after of CsA withdrawal [49]. In the
study of Tugwell et al, one patient was withdrawn from the
study because of significant renal dysfunction that did not
respond to dose reduction [63]. After CsA withdrawal,
serum creatinine dropped, but was still 20% above baseline
level. In the remaining patients, serum creatinine fell to
within 15% of baseline, except in 2 patients.
Risk difference of CsA-induced nephrotoxicity. To deter-
mine the risk difference for CsA-induced nephrotoxicity,
data were used from 13 of the 18 selected articles where the
peak rises in serum creatinine were available from each
patient in the CsA and control groups [10, 48–53, 55–58,
60, 62].
Nephrotoxicity was defined as an increase in serum
creatinine level of 50% or more above baseline, at least
once during the study period. In the CsA-treated group,
102 of 474 patients (21.5%) exhibited such a rise in serum
creatinine, compared to 5 of 393 patients (1.3%) in the
control group (Fig. 1). The weighted average risk differ-
ence in developing nephrotoxicity between CsA treatment
and an alternative therapy was 15.4% with a 95% confi-
dence interval of 11.8% to 18.8%. Visual analysis of the
results showed heterogeneity, which was confirmed by
homogeneity testing: Q 5 77.4 (P , 0.01). Therefore, a
correction factor t was determined, t 5 0.0242. With the t
factor being an estimate of the degree of variability, the risk
difference was then recalculated. The corrected risk differ-
ence was 20.9% with a 95% confidence interval of 11.6 to
30.2%.
Morphological evaluation of cyclosporine A-induced
nephrotoxicity
Of the 19 articles in which renal morphological evalua-
tion was reported, 10 papers were selected according to the
criteria mentioned in the methodology (Table 5) [8, 21,
65–72]. An Advisory Board of Pathologists agreed that the
most frequently found lesions are interstitial fibrosis, tubu-
lar atrophy and arteriolar hyalinosis [73].
All the selected papers reported these lesions as being
mild to moderate. Only one study, by Landewe´ et al found
no significant differences between biopsies of CsA-treated
rheumatoid arthritis patients and autopsy material of non-
CsA-treated rheumatoid arthritis patients [67].
The three studies with a pre-treatment and post-treat-
ment biopsy described either an increase or a development
of renal morphological lesions. Svarstad et al [71], and
Zachariae et al [72] found a de novo interstitial fibrosis and
tubular atrophy in respectively 40% and 65% of CsA-
treated patients after one year of treatment with a CsA
dose of # 5 mg/kg. Sund et al found an increase in
interstitial fibrosis in function of time, in four out of ten
patients, when comparing baseline kidney biopsies versus
biopsies at one year and three years of CsA-therapy [70].
Table 4. Renal functional parameters of selected studies
Study Date Ref.
Serum creatinine mg/dl
Patients Controls Return to
baseline after
CsA stop
start
CsA
end
CsA
%
increase start end
%
increase
Ahern MJ et al 1991 [47] 0.90 1.13 26 0.90 0.90 0 Partial
Berg KJ et al 1986 [48] 0.70 1.00 43 0.75 0.80 7 Partial
Berg KJ et al 1989 [49] 0.93 1.11 19 0.97 1.01 4 Partial
Boers M et al 1990 [50] 0.76 0.93 22 0.81 0.81 0 Total
Brynskov J et al 1989 [10] 0.91 1.04 14 0.96 0.99 3 Total
de Vries J et al 1990 [51] NA NA NA NA NA NA Not mentioned
Dijkmans BAC et al 1987 [52] 0.82 0.95 16 0.81 0.81 0 Partial
Dougados M et al 1988 [53] 0.92 1.19 29 0.90 0.90 0 Not mentioned
Feagan BG et al 1994 [54] 0.89 1.03 16 0.89 0.89 0 Total
Ferraccioli G et al 1995 [55] 0.94 0.97 3 0.96 0.99 3 Not mentioned
Finzi A et al 1993 [56] 0.93 1.00 7 0.94 0.91 23 Total
Førre Ø et al 1994 [57] 0.88 1.12 28 0.89 0.91 2 Partial
Heule F et al 1988 [58] 0.88 0.96 9 0.90 0.88 23 Partial
Jewell DP et al 1994 [59] 0.91 0.98 8 0.91 0.92 1 Not mentioned
Kru¨ger K et al 1994 [60] 0.77 1.00 30 NA NA 0 Total
Landewe´ RBM et al 1994 [61] 0.86 1.01 17 0.83 1.00 20 Not mentioned
Mahrle G et al 1995 [62] 0.92 0.98 7 0.94 0.94 0 Total
Tugwell P et al 1990 [63] 0.81 1.03 27 0.79 0.84 6 Partial
Total (weighted) 0.87 1.02 17 0.88 0.9 1.7
NA is not available.
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DISCUSSION
Cyclosporine A is used with moderate to excellent result
in the different auto-immune diseases [4–17]. As men-
tioned in the Results section, multiple open and controlled
studies, reviews and letters have been reported. Although
the initial objective of these papers was to demonstrate the
efficacy of CsA, they mention nephrotoxicity as possible
side effect of CsA. However, the risk-benefit ratio of CsA is
obviously much more critical in some auto-immune dis-
eases in comparison to transplantation medicine.
The present meta-analysis unequivocally demonstrates
the potential risk of CsA to induce a substantial impair-
ment in renal function in patients with auto-immune dis-
eases. The weighted percentage increase in serum creati-
nine level of all studies at the end of the treatment period
was 17% in the CsA-treated group and 1.7% in the control
group. A risk difference of 20.9% between a therapy with
CsA and an alternative therapy for developing an increase
of 50% in serum creatinine level indicates a serious neph-
rotoxic potential. This risk difference reflects mainly the
acute, reversible form of nephrotoxicity, since thirteen of
the selected studies reported reversibility of the renal
functional impairment. However, in seven of these studies,
this reversibility was only partial, and serum creatinine was
still significantly above baseline level one to two years after
CsA withdrawal. This could herald the evolution to pro-
gressive renal injury.
The presently calculated risk difference implies an un-
derestimation of the issue of CsA-induced nephrotoxicity,
since we used a rather strict definition of nephrotoxicity. It
must be kept in mind that a slight increase in serum
creatinine reflects a substantial decrease in renal function.
Moreover, one has to take into consideration that all of the
selected studies applied dose adjustments whenever serum
creatinine increased to more than 30 to 50% over the
patient’s own baseline value, according to the general
consensus [22, 23]. This indicates that dose reduction is not
sufficient to prevent nephrotoxicity.
Only five of all the control patients (393 patients)
exhibited a rise of 50% or more in serum creatinine level
during the study period. One was a patient receiving
placebo in the study of de Vries et al [51], and the other
four received a treatment with etretinate in the study of
Mahrle et al [62]. No explanation for these findings were
given in the publications.
The higher serum creatinine increase in the chloroquine-
treated control group compared to the CsA-treated group
in the study of Landewe´ et al [61] could be explained by the
Fig. 1. Risk difference for developing nephrotoxicity between cyclosporine A treatment and an alternative therapy. *Number of patients with at least
one rise in serum creatinine .50%/total.
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competition of the organic acid chloroquine with the renal
secretion of creatinine.
The results of this meta-analysis raise the question of
whether there may be a subset of patients who are more
susceptible to CsA-induced nephrotoxicity. Although the
concept of risk factors is not addressed in this meta-
analysis, one can find several possible risk factors in the
literature: pre-treatment renal functional impairment, high
CsA dose and elevated blood levels of CsA, age, hyperten-
sion, and co-medication with other nephrotoxic drugs [74,
75]. The nephrotoxic potential of NSAIDs has been known
for a long time, but 5-ASA can also lead to renal lesions
[76]. In the selected studies, NSAIDs and 5-ASA were
given in equal doses and to an equal number of patients
in the CsA treated and in the control groups, so that
possible nephrotoxic effects are equal in both groups.
Nevertheless, NSAIDs might potentiate the nephrotoxic
effects of CsA through an inhibition of prostaglandin
production [77].
One limitation of a meta-analysis is a potential suscepti-
bility to publication bias. A comprehensive literature search
was done in two different medical literature systems and
reference lists. We searched for unpublished studies by
communicating with some experts in the field (a.o. the
Table 5. Studies describing morphological cyclosporine A-induced renal lesions
Study Date Ref. Disease Control group
N
patients
N
controls CsA dose
(mean)
mg/kg/day
Time of
biopsy
months of
CsA
treatment
Functional
impairment Lesions
Repeat
biopsy?mean age
Studies with control group
Andersen CB 1991 [65] AI-uveitis Cadaveric
kidney
donors
10 (42) 11 (46) max. 10 33 / Mild; chronicity index
significant higher in
CsA group
2
Int. Kidney Biopsy
Registry
1990 [66] Psoriasis Psoriasis
patients
14 (40) 16 (43) 3.9 15 40% (SCr) Minimal to slight;
slight difference
between both
groups
2
Int. Kidney Biopsy
Registry
1993 [21] RA RA patients
and cadaveric
kidney
donors
40 (50) 11 (49)
41 (—)
3.4 17 12%
(estimated
CCr)
3/10 patients:
moderate to severe;
other patients: mild
lesions
2
Landewe´ RBM 1996 [67] RA Autopsy
material of
RA patients
11 (51) 22 (56) 3.3 26 26%
(estimated
CCr)
Mild to moderate; no
significant
difference between
both groups
2
Messana JM 1995 [68] Psoriasis Patients with
different
auto-immune
diseases
20 (44) 40 (—) 4.1 / 12% (GFR) 4/20 patients:
moderate to severe;
other patients: nil
to slight
2
Palestine AG 1986 [8] AI-uveitis Non-diagnostic
renal biopsies
of patients
with
hematuria
17 (36) 20 (32) 10 24 50% (SCr) Variable interstitial
fibrosis and tubular
atrophy in all
patients
2
Young EW 1994 [69] Psoriasis Psoriasis
patients and
cadaveric
kidney
donors
19 (43) 16 (43)
38 (45)
3.9 12 1 36 17% (GFR) Significant higher
scores for CsA-
treated group in
interstitial fibrosis
and tubular atrophy
1
Studies with biopsy before and after CsA-treatment in CsA-group:
Sund S 1994 [70] RA 10 (52) / 4 0 1 18
1 39
/ 4/10 patients: slight to
moderate (increase
compared to pre-
treatment biopsy)
1
Svarstad E 1994 [71] Psoriasis 10 (—) / 3.23 0 1 12 17% (GFR) 4/10 patients: slight de
novo interstitial
fibrosis; 3/10
patients: slight
tubular atrophy
2
Zachariae H 1992 [72] Psoriasis 12 (38) / max. 6 0 1 12 12%
(estimated
CCr)
8/12 patients: mild de
novo interstitial
fibrosis; 4/12
patients: slight art.
hyalinosis
2
Abbreviations are: RA, rheumatoid arthritis; AI, auto-immune; SCr, serum creatinine; CCr, creatinine clearance.
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Cochrane Renal Review Group), but retrieved no addi-
tional data. In addition, not all authors responded to our
inquiries for missing data, and thus some trials are more
accurately represented than others. It was not always clear
whether or not the different authors applied an intention-
to-treat analysis, which can be an obvious source of bias.
It may appear that complete homogeneity of studies is a
desirable goal of a meta-analysis, but this need not always
be the case, as stated in a commentary of Moher and Olkin
[78]. There has to be an identification of the sources of
heterogeneity. Possible explanations for the encountered
heterogeneity in the present study are differences in the
dose and treatment period, and also different study popu-
lations (psoriasis, RA, Crohn’s disease, uveitis). Expressing
the results in risk difference, instead of an odds ratio,
inherently also leads to more heterogeneity. As can be seen
in Figure 1, however, the risk differences of the selected
studies are all but one on the same side of the zero line, and
although this is not always significant for every study, it
indicates the same tendency, making the analysis more
consistent and reliable [79, 80].
As Bailar stated in a recent editorial, the best way to
report a meta-analysis is to present the results into a Figure
expressing the risk ratios or differences [81]. The reduction
of these results to one single parameter must be interpreted
with care [79, 81].
Besides the acute, functional repercussions of CsA on
the kidney, one has to consider the possibility of CsA-
induced morphological renal lesions in patients with auto-
immune diseases, which are well described in organ trans-
plantation [82]. The review of the morphological studies
clearly indicates that CsA can induce morphological, renal
lesions such as interstitial fibrosis, tubular atrophy and
arteriolar hyalinosis. These lesions, however, are not spe-
cific for CsA-induced nephropathy, and can be observed in
advanced stages of many renal diseases. Also, rheumatoid
arthritis itself can lead to renal morphological alterations
(nephrosclerosis, amyloidosis and also tubulointerstitial
lesions) [83, 84]. Moreover, it should be noted that patients
with psoriatic or rheumatoid arthritis could exhibit tubulo-
interstitial lesions induced by NSAIDs or analgesics. There-
fore, studies comparing kidney biopsies of CsA-treated
patients before and after treatment are most appropriate to
investigate CsA-induced renal histologic alterations. Svars-
tad et al [71], and Zachariae et al [72] found a de novo
interstitial fibrosis and tubular atrophy in respectively 40%
and 65% of CsA-treated patients after one year of treat-
ment with a CsA dose of # 5 mg/kg. After a maintenance
therapy of several years, the CsA-induced lesions (mainly
interstitial fibrosis) are increasing, as reported by Sund et al
[70], and Young et al [69], perhaps even after CsA-
withdrawal. Landewe´ et al [67], found no significant differ-
ences between biopsies of CsA-treated rheumatoid arthritis
patients and autopsy material of non-CsA-treated rheuma-
toid arthritis patients. However, they did not mention the
cause of death in their control group, and more impor-
tantly, no kidney biopsies were performed in the patients
withdrawn from CsA treatment due to renal functional
impairment.
In a recent study, Zachariae et al reported that no
patient with psoriasis treated for two years or more with
CsA had a normal kidney biopsy specimen, despite normal
pretreatment morphology in 17 of the 25 patients [85].
Over the years, a significant increase in arteriolar hyalinosis
and interstitial fibrosis was detected. Interstitial fibrosis was
severe in 5 and moderate in the remaining 6 of 11 patients
treated for four years or more. In the same group glomer-
ular sclerosis was pronounced.
Overall, the analysis of the different morphological stud-
ies shows that already after 12 months of low-dose CsA (#5
mg/kg/day), de novo nonspecific morphological damage can
be induced in patients with auto-immune diseases.
Conclusions
From this analysis of the literature, it is obvious that
maintenance therapy with CsA in patients affected by
auto-immune diseases, is not without risk. A rigorous
evaluation of the risk-benefit ratio is strongly recom-
mended for each patient, with strict pre-treatment clinical
and laboratory evaluation of each patient, especially with
regards to renal function. Regular follow-up during CsA-
therapy with determination of serum creatinine and mon-
itoring of CsA trough levels is mandatory. Monitoring CsA
trough levels is especially important in case of possible drug
interactions or liver disease, and high trough levels must
lead to dose reductions. We advocate that the guidelines of
the different consensus reports would be followed strictly
[22, 23]. Renal biopsies during treatment must be seriously
taken into consideration in patients who develop even
slight renal functional impairment, particularly when pro-
longed therapy of longer than one year, even with low dose
CsA (#5 mg/kg/day) is given.
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APPENDIX
Calculation of risk difference
For k clinical trials, each trial provides the number of
patients in each treatment group (NCsA and Ncont) and the
rate at which some event occurs within that group (SCsA
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and Scont) [26]. For each trial, the risk difference (RD) is
equal to SCsA 2 Scont. The variance of RD is the sum of the
variances of the rates calculated for the cyclosporine A and
control groups and is calculated as follows:
VarRD 5 SCsA z ~1 2 SCsA)/NCsA 1 Scont
z ~1 2 Scont!/NCont
and WRD is calculated as follows:
WRD 5 1/VarRD for each study
The weighted mean RD is given by the following equation:
Mean RD 5 S~RD z WRD!/S WRD for k studies
A measure of study heterogeneity, Q, can then be calcu-
lated as follows:
Q 5 S@WRD z ~RD 2 mean RD!2#
If the studies are relatively homogeneous, each separate
study estimates the same mean RD, and the variance
among individual studies approaches zero. Q follows an
approximate X2 distribution with k-1 df. When heteroge-
neity exists (and it nearly always exists), the method of
moments is used to calculate an estimate of among study
variance, t.
t 5 max $0,~Q 2 @k 2 1#!/~SWRD
2 ~S@WRD#2/SWRD!)}
A corrected value of WRD for each of k studies is calculated
as follows:
WRDcorr 5 1/~VarRD 1 t!
The corrected weighted mean risk difference is given by:
Mean RDcorr 5 S~RD z WRDcorr!/SWRDcorr
for each of the R studies and
SE 5 1/Î( WRDcorr
with an approximate 95% confidence interval given by:
Mean RDcorr 6 1.96 z SE
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